Safety first: pIOL is effective for myopic astigmatism

Article

Implantation of the Artiflex toric iris-fixated phakic IOL is effective, predictable and safe for the correction of myopic astigmatism.

Implantation of the Artiflex toric iris-fixated phakic IOL is effective, predictable and safe for the correction of myopic astigmatism, claims a study in the Journal of Cataract and Refractive Surgery.

Dr Gonzalo Muñoz et al., Refractive Surgery Department, Marqués de Sotelo Ophthalmic Clinic, Barcelona, Spain, conducted a cohort study on 42 eyes of 25 patients age 21 to 39 years.

Refraction, uncorrected (UDVA) and corrected (CDVA) distance visual acuities, complications, pIOL misalignment, and endothelial cell count (ECC) were evaluated 12 months postoperatively. Vector analysis was used to calculate indices of success and misalignment.

Mean spherical equivalent was reduced from −8.85 D ± 2.71 SD to −0.37 ± 0.46 D, with 66.7% of the eyes within ±0.50 D. Mean cylinder power reduced from−2.90 D to −0.39 D. A UDVA of 0.5 or better was achieved in all eyes, along with a CDVA of 0.8 or better.

Mean clinical pIOL misalignment was 2.6 ± 1.8 degrees and one eye required surgical repositioning of the pIOL. Mean ECC reduction was 9.3% ± 1.8%, with iris pigment precipitates observed in 16.7% of eyes. Vector analysis demonstrated excellent mean indices of success for overall, spherical and astigmatic corrections.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.